MEDIPHARM LABS CORP (LABS.CA) Fundamental Analysis & Valuation

TSX:LABS • CA58504D1006

Current stock price

0.065 CAD
-0.01 (-7.14%)
Last:

This LABS.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. LABS.CA Profitability Analysis

1.1 Basic Checks

  • LABS had negative earnings in the past year.
  • LABS had a negative operating cash flow in the past year.
  • LABS had negative earnings in each of the past 5 years.
  • LABS had a negative operating cash flow in each of the past 5 years.
LABS.CA Yearly Net Income VS EBIT VS OCF VS FCFLABS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • LABS's Return On Assets of -18.07% is on the low side compared to the rest of the industry. LABS is outperformed by 67.74% of its industry peers.
  • Looking at the Return On Equity, with a value of -23.08%, LABS is in line with its industry, outperforming 45.16% of the companies in the same industry.
Industry RankSector Rank
ROA -18.07%
ROE -23.08%
ROIC N/A
ROA(3y)-19.48%
ROA(5y)-32.71%
ROE(3y)-24.18%
ROE(5y)-38.41%
ROIC(3y)N/A
ROIC(5y)N/A
LABS.CA Yearly ROA, ROE, ROICLABS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • LABS has a Gross Margin of 27.02%. This is comparable to the rest of the industry: LABS outperforms 41.94% of its industry peers.
  • LABS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LABS.CA Yearly Profit, Operating, Gross MarginsLABS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200 -250

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. LABS.CA Health Analysis

2.1 Basic Checks

  • LABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LABS has more shares outstanding than it did 1 year ago.
  • LABS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for LABS has been reduced compared to a year ago.
LABS.CA Yearly Shares OutstandingLABS.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
LABS.CA Yearly Total Debt VS Total AssetsLABS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • LABS has an Altman-Z score of -2.70. This is a bad value and indicates that LABS is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -2.70, LABS is doing worse than 70.97% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that LABS is not too dependend on debt financing.
  • LABS has a better Debt to Equity ratio (0.00) than 87.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.7
ROIC/WACCN/A
WACC8.81%
LABS.CA Yearly LT Debt VS Equity VS FCFLABS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • LABS has a Current Ratio of 2.77. This indicates that LABS is financially healthy and has no problem in meeting its short term obligations.
  • LABS has a better Current ratio (2.77) than 67.74% of its industry peers.
  • LABS has a Quick Ratio of 1.96. This is a normal value and indicates that LABS is financially healthy and should not expect problems in meeting its short term obligations.
  • LABS has a better Quick ratio (1.96) than 77.42% of its industry peers.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 1.96
LABS.CA Yearly Current Assets VS Current LiabilitesLABS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. LABS.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 35.00% over the past year.
  • Looking at the last year, LABS shows a small growth in Revenue. The Revenue has grown by 7.54% in the last year.
  • LABS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.62% yearly.
EPS 1Y (TTM)35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)7.54%
Revenue growth 3Y26.86%
Revenue growth 5Y4.62%
Sales Q2Q%-8.14%

3.2 Future

  • Based on estimates for the next years, LABS will show a very strong growth in Earnings Per Share. The EPS will grow by 31.35% on average per year.
  • The Revenue is expected to decrease by -2.18% on average over the next years.
EPS Next Y68.62%
EPS Next 2Y31.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-15.76%
Revenue Next 2Y-2.18%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LABS.CA Yearly Revenue VS EstimatesLABS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
LABS.CA Yearly EPS VS EstimatesLABS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.1 -0.2 -0.3

More info and screens

Find the best growth stocksShow best growing peers

1

4. LABS.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • LABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LABS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LABS.CA Price Earnings VS Forward Price EarningsLABS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LABS.CA Per share dataLABS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 0.06 0.08 0.1

4.3 Compensation for Growth

  • LABS's earnings are expected to grow with 31.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.35%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LABS.CA Dividend Analysis

5.1 Amount

  • LABS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LABS.CA Fundamentals: All Metrics, Ratios and Statistics

MEDIPHARM LABS CORP

TSX:LABS (4/24/2026, 7:00:00 PM)

0.065

-0.01 (-7.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-30
Earnings (Next)05-18
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.28%
Ins Owner ChangeN/A
Market Cap27.62M
Revenue(TTM)45.12M
Net Income(TTM)-8.27M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-185.95%
Min EPS beat(2)-226.8%
Max EPS beat(2)-145.1%
EPS beat(4)1
Avg EPS beat(4)-171.65%
Min EPS beat(4)-390.2%
Max EPS beat(4)75.49%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.62%
Min Revenue beat(2)-8.27%
Max Revenue beat(2)1.03%
Revenue beat(4)3
Avg Revenue beat(4)1.4%
Min Revenue beat(4)-8.27%
Max Revenue beat(4)12.35%
Revenue beat(8)5
Avg Revenue beat(8)-0.9%
Revenue beat(12)6
Avg Revenue beat(12)-5.12%
Revenue beat(16)7
Avg Revenue beat(16)-4.01%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-60%
EPS NY rev (3m)-60%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-27.24%
Revenue NY rev (3m)-27.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.61
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 0.79
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.11
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -18.07%
ROE -23.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.02%
FCFM N/A
ROA(3y)-19.48%
ROA(5y)-32.71%
ROE(3y)-24.18%
ROE(5y)-38.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.02%
Cap/Sales 0.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 1.96
Altman-Z -2.7
F-Score4
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)10.22%
Cap/Depr(5y)14.9%
Cap/Sales(3y)0.67%
Cap/Sales(5y)1.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y68.62%
EPS Next 2Y31.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.54%
Revenue growth 3Y26.86%
Revenue growth 5Y4.62%
Sales Q2Q%-8.14%
Revenue Next Year-15.76%
Revenue Next 2Y-2.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-14.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.58%
OCF growth 3YN/A
OCF growth 5YN/A

MEDIPHARM LABS CORP / LABS.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDIPHARM LABS CORP (LABS.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LABS.CA.


What is the valuation status for LABS stock?

ChartMill assigns a valuation rating of 1 / 10 to MEDIPHARM LABS CORP (LABS.CA). This can be considered as Overvalued.


Can you provide the profitability details for MEDIPHARM LABS CORP?

MEDIPHARM LABS CORP (LABS.CA) has a profitability rating of 1 / 10.


Can you provide the financial health for LABS stock?

The financial health rating of MEDIPHARM LABS CORP (LABS.CA) is 4 / 10.


What is the expected EPS growth for MEDIPHARM LABS CORP (LABS.CA) stock?

The Earnings per Share (EPS) of MEDIPHARM LABS CORP (LABS.CA) is expected to grow by 68.62% in the next year.